Abstract. Oral cavity carcinoma (OCC) is one of the most common causes of cancer-related death worldwide and has poor clinical outcome after standard therapies. Therefore, new prognostic biomarkers and therapeutic targets for OCC are urgently needed. We selected cell division cycle associated 1 (CDCA1) as a candidate OCC biomarker. Immunohistochemical analysis confirmed that CDCA1 protein was expressed in 67 of 99 OCC tissues (67.7%), but not in healthy oral epithelia. CDCA1 expression was significantly associated with poor prognosis in OCC patients (P=0.0244). Knockdown of CDCA1 by siRNAs significantly increased apoptosis of tumor cells. These data suggest that CDCA1 represents a novel prognostic biomarker and therapeutic target for OCC.
Introduction
Oral cavity carcinoma (OCC) is the most common malignant cancer worldwide, with 28,030 new cases and 5,850 deaths per year in the United States (1) . OCC prevalence is increasing for many reasons, including excessive alcohol consumption, excessive smoking, human papilloma virus infection and lack of hygiene (2) . Smoking and alcohol consumption are the main contributors to the rising prevalence of OCC (3) (4) (5) (6) . The 5-year survival rate of OCC is 75-90% for stage I and 10-22% for stage IV (7, 8) . Surgery followed by radiotherapy is the primary treatment for early and localized advanced OCC. However, local and regional recurrences are reported in 90% of cases after surgery and radiotherapy treatment (9) . Adjuvant chemotherapy after surgery improved survival of OCC patients by 16% (10) . Despite recent developments in treatment, the overall survival of OCC has improved by just 5% in the last 20 years (6, 11) . Therefore, treatments for OCC clearly need to be improved; more personalized therapies and novel molecular therapies with fewer adverse events may represent more effective approaches (12) .
To isolate potential molecular targets for the diagnosis and/or treatment of OCC, we performed genome-wide gene expression analyses and tissue microarray analyses of various solid tumor tissues. We identified several oncoantigens involved in the development and/or progression of cancer . Cell division cycle associated 1 (CDCA1) mRNA was overexpressed in cancer tissues, including OCC, colorectal, lung cancer, cholangiocellular carcinoma and urological cancer (33) (34) (35) (36) . In addition, HLA-A0201-restricted epitope peptides from the CDCA1 protein induced peptidespecific cytotoxic T lymphocytes, implicating CDCA1 as a likely target for molecular targeted therapy and/or immunotherapy (36) . CDCA1 is a component of the Ndc80 complex, which contains two subcomplexes: (KNTC2)-NUF2 (CDCA1) and SPC24-SPC25. The NCD80 complex is involved in chromosome segregation and the spindle checkpoint (37) . The attachment of CDCA1 to the kinetochore outer plate generates microtubule-dependent forces for chromosomal movement and protein assembly at the kinetochore during the spindle checkpoint. CDCA1 is expressed in human cancers, but its specific role in OCC growth/survival or the clinical significance of CDCA1 protein as a tissue biomarker for OCC has not been determined (38, 39) .
In the present study, we report that CDCA1 plays an essential role in the malignant potential and survival of OCC, and represents a promising diagnostic and prognostic tissue biomarker. In addition, CDCA1 is a potential therapeutic target for new molecular targeted therapies for OCC. Immunocytochemical analysis. Cultured cells were washed twice with PBS(-), fixed in 4% paraformaldehyde solution for 10 min at 37˚C, and permeabilized in PBS(-) containing 0.1% Triton X-100 for 3 min. Non-specific binding sites were blocked with blocking solution (CAS Block; Invitrogen, Carlsbad, CA, USA) for 10 min at room temperature before incubating with human CDCA1 antibody solution for 1 h at room temperature. Alexa Fluor 488-conjugated goat anti-rabbit secondary antibody (Molecular Probes, Eugene, OR, USA) was added to detect endogenous CDCA1. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA, USA). CDCA1 antibody staining was visualized with a fluorescence microscope (BZ-X710; Keyence, Osaka, Japan).
Materials and methods

Cell
Immunohistochemistry and tissue microarray analysis.
Tumor tissue microarrays were constructed using 99 formalin-fixed primary OCC tissues, which were removed during curative surgery without neoadjuvant chemotherapy. Tumor tissue microarrays were constructed according to the previously published procedures (13) . To measure CDCA1 protein expression in paraffin-embedded OCC samples, we performed immunohistochemistry using a rabbit anti-CDCA1 antibody and the EnVision HRP kit (DakoCytomation A/S, Glostrup, Denmark). For antigen retrieval, slides were boiled in retrieval solution (DakoCytomation). A rabbit polyclonal anti-CDCA1 antibody was added to each slide after blocking endogenous peroxidase activity and unspecific binding sites. After primary antibody incubation, sections were incubated with an HRP-labeled anti-rabbit IgG secondary antibody (DakoCytomation). Substrate-chromogen was added to visualize labeled proteins and the specimens were counterstained with hematoxylin. The intensity of staining within each tumor tissue core was mostly homogeneous, therefore, the intensity of CDCA1 staining was semi-quantitatively evaluated by two independent investigators without prior knowledge of the clinicopathological data. Expression was recorded as absent, weak or strong. Statistical analysis. We used contingency tables to correlate clinicopathological variables, (e.g., gender, age, region and pathological TNM stage), with CDCA1 protein expression levels determined by tissue microarray analysis. Survival curves were generated on the basis of the date of surgery or diagnosis to the time of death, or to the last follow-up observation. Kaplan-Meier curves were calculated for each relevant variable and for CDCA1 expression in oral tumors. Differences in survival times among patient subgroups were analyzed using the log-rank test. Univariate and multivariate analyses were performed with the Cox proportional hazard regression model to determine associations between clinicopathological variables and cancer-related mortality.
RNA interference assay. We transfected siRNAs (SigmaAldrich, St. Louis, MO, USA) into HSC4 and Ca9-22 cells, using Lipofectamine 2000 reagent (Invitrogen). The target sequences of the synthetic oligonucleotides for RNA interference were as follows: control 1 (luciferase: LUC) 5'-CGUACG CGGAAUACUUCGATT-3'; control 2 (EGFP) 5'-GAAGCAG CACGACUUCUUCTT-3'; siRNA-CDCA1-#1, 5'-AAGAUG CUGCUGAAAGGGAGATT-3'; siRNA-CDCA1-#2, 5'-GAA GUCAUGUUCCACAUUTT-3'. Five days after transfection, cell proliferation was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Dojindo Molecular Technologies) and colony formation assays.
Flow cytometry. The cell cycle of OCC cells was analyzed using a Cycletest Plus DNA reagent kit (BD Biosciences, San Jose, CA, USA). Ca9-22 and HSC4 cells were transfected with si-CDCA1 or si-LUC. Seventy-two hours after siRNA transfection, 5x10 5 cells/ml were collected for measuring DNA ploidy. Cell cycle analysis was performed within 3 h using a BD FACSVerse flow cytometer. The DNA content of cells selected from at least 20,000 ungated cells was measured.
Live cell imaging. HSC4 cells were seeded into 35-mm glass dishes in RPMI containing 10% FBS. To investigate apoptosis 48 h after transfecting CDCA1 siRNA or control siRNA into HSC4 cells, we performed time-lapse imaging to detect the apoptotic cells using EVOS FL Auto cell imaging system (Life Technologies, Carlsbad, CA, USA). We captured images every 20 min for up to 96 h.
Results
Expression of CDCA1 in OCC cells and tissues. CDCA1
mRNA was upregulated in six of the seven OCC cell lines, but expression was hardly detectable in healthy oral epithelial cells by real-time PCR (Fig. 1A) . We confirmed increased CDCA1 expression in all eight OCC tissues by real-time PCR and very low expression in healthy tongue tissue (Fig. 1B) . In addition, CDCA1 protein was strongly expressed in five out of six OCC cell lines using western blotting (Fig. 1C) . Furthermore, immunocytochemical staining showed that CDCA1 protein was mainly located in nucleus of Ca9-22, HSC4 and SCC9 cells, but no expression was detected in HSC2 and human oral mucosa keratinocytes (HOMK) cells (Fig. 1D) . Table II . Association of CDCA1 protein expression in OCC tissues with the patient characteristics (n=99). 3%) . In contrast, the adjacent healthy tongue epithelial tissues were not stained ( Fig. 2A) . Next, we assessed the association of CDCA1 protein expression with the clinical parameters. Age factor (higher in ≥65 years; P= 0.0063 by Fisher's exact test), pT factor (higher in T3-T4; P= 0.0112 by Fisher's exact test), and pN factor (higher in N1 and N2; P= 0.0282 by Fisher's exact test) were significantly related to strong CDCA1 expression (Table II) . Furthermore, strong CDCA1 expression was also significantly correlated with shorter survival compared with weak/absent CDCA1 expression (P= 0.0244 by log-rank test; Fig. 2B ). We also performed univariate analysis to investigate the correlation between patient prognosis and other factors, including age (<65 vs. ≥65 years), gender (female vs. male), region (tongue vs. other), pT classification (T1+T2 vs. T3+T4), pN classification (N0 vs. N1+N2) and CDCA1 expression status (strong vs. weak/absent). Among these parameters, strong CDCA1 expression (P= 0.0310), advanced pT stage (P= 0.0080) and advanced pN stage (P= 0.0474) were significantly associated with poor prognosis (Table III) .
CDCA1 protein P-value strong ------------------------------------------------------------------------------------------------------------------------------------------------
Inhibition of the growth of OCC cells by knockdown of CDCA1 expression.
To assess whether upregulation of CDCA1 played a significant role in the growth of OCC cells, we transfected CDCA1 siRNAs (si-CDCA1-#1 and si-CDCA1-#2) and control siRNAs (si-LUC and si-EGFP) into HSC4 and Ca9-22 cells. CDCA1 protein expression was reduced by siRNA-mediated knockdown ( Fig. 3A and B) . Suppression of CDCA1 protein expression significantly inhibited cell viability in HSC4 and Ca9-22 cells compared with controls (P<0.0001 in both cell types) (Fig. 3C and D) . In addition, colony formation assays demonstrated that reduced CDCA1 expression decreased the growth of HSC4 and Ca9-22 cells compared with controls ( Fig. 3E and F) .
To analyze the effects of CDCA1 on the cell cycle, flow cytometric analysis of HSC4 and Ca9-22 cells was performed 72 h after siRNA transfection. The proportion of cells in the sub-G1 phase was significantly higher in si-CDCA1-transfected HSC4 and Ca9-22 cells than in controls (P<0.0001 and P= 0.0003, respectively) ( Fig. 4A and B) . The number of apoptotic HSC4 and Ca9-22 cells was significantly higher after siRNA-mediated CDCA1 knockdown than in control cells (P=0.0019 and P=0.0005, respectively) ( Fig. 4C and D) . In addition, the caspase-3/-7 green assay demonstrated increased activation of caspase-3/-7 in OCC cells transfected with si-CDCA1 compared with control siRNAs (Fig. 4E and F) .
To further clarify the effect of CDCA1 knockdown on cellular morphology and cell cycle, we performed live cell imaging of HSC4 cells transfected with CDCA1 siRNA using time-lapse microscopy. Dynamic HSC4 cell growth and survival were observed up to 96 h after siRNA transfection. Mitotic cells were observed 69 h after control-siRNA (si-LUC) transfection in HSC4 cells (white arrow). Daughter cells transfected with si-CDCA1 died (black arrow) after cell division, whereas cells transfected with control siRNAs survived (Fig. 5A ). In addition, apoptosis-related proteins, including Bad, Bax, cleaved caspase-3, TRAIL R2/DR5 and cyclindependent kinase inhibitor 1A (CDKN1A) were enhanced in cells transfected with si-CDCA1 compared with control siRNAs (Fig. 5B and C) . overall survival of OCC patients, but they have limited efficacy and induce drug resistance. Therefore, new therapeutic target drugs for OCC are essential for improving the clinical outcome for patients.
In the present study, CDCA1 was overexpressed in OCC tissues and CDCA1 overexpression was significantly associated with poor prognosis. Furthermore, suppressing CDCA1 reduced OCC cell growth and promoted apoptosis. cBioportal for Cancer Genomics database (http://www.cbioportal.org/) revealed that CDCA1 upregulation correlated significantly with poorer prognosis for head and neck cancer, thus, independently supported a prognostic potential of CDCA1 as a biomarker for OCC. To examine mechanism of CDCA1 activation in OCC, we collected comparative genome hybridization and genome sequencing data for CDCA1 (http://cancer.sanger. ac.uk/cosmic/gene/). Missense mutations in CDCA1 were detected in 0.78% of OCC tissues (2/255 cases), but no CDCA1 gene amplification or translocation was reported. Therefore, CDCA1 overexpression could be involved in an important epigenetic mechanism contributing to OCC.
CDCA1 is a highly conserved component of a nuclear division cycle complex and is categorized as an oncoantigen. We showed that suppression of CDCA1 significantly inhibited OCC cell growth and induced apoptosis in OCC cells, but the specific mechanisms remain unclear. According to our findings and previous studies, possible mechanisms exist for CDCA1-mediated regulation of OCC growth and survival: i) stable spindle microtubule-kinetochore attachment in mitotic prophase of highly proliferative cancer cells; ii) regulation of apoptosis pathways. CDCA1 protein belongs to the NDC80 complex, which contains CDCA1, HEC1, SPC24 and SPC25. CDCA1-HEC1 heterodimers interact with the plus ends of spindle microtubules and SPC24-SPC25 heterodimers anchor the complex into the kinetochore (40) . CDCA1 plays a pivotal role in stable spindle microtubule-kinetochore attachment and stable microtubule localization of centromere-associated protein E (CENP-E) (41) . Decreased CDCA1 expression inhibited kinetochore attachment to spindle microtubules, resulting in aberrant chromosome segregation, prolonged mitotic blockade and cell death (42) (43) (44) (45) . In the early phase of mitosis, after kinetochore attachment to spindle microtubules, this complex is stable and has a half-life of several minutes, which is essential for the next phase of mitosis. However, the complex is unstable and has a half-life of approximately 10 sec when binding of the kinetochore to microtubules is impaired. This leads to abnormal cell division, resulting in dysfunctional daughter cells that eventually die. In agreement with previous findings, CDCA1 knockdown in OCC cells resulted in impaired growth and apoptosis in cells. Downregulation of CDCA1 increased the expression of apoptosis-related proteins in OCC cells, including Bad, Bax, cleaved caspase-3 and TRAIL R2/DR5. The data suggested the dysregulation of appropriate cell division and subsequent induction of apoptosis of OCC cells through various mechanisms such as mitochondrial-dependent and caspase-dependent pathways.
In summary, CDCA1 is likely to play a significant role in OCC carcinogenesis. Importantly, CDCA1 is associated with growth and survival of OCC cells. Since CDCA1 was not expressed in healthy tissues, apart from the testis (33) , it could be a highly specific cancer biomarker. In addition, targeting CDCA1 will lead to the development of new type of therapeutic agents for OCC, such as immunotherapies as well as molecular targeted drugs (46) .
